Cargando…
Ranirestat for the Management of Diabetic Sensorimotor Polyneuropathy
OBJECTIVE: Aldose reductase inhibitors (ARIs) are potential disease modifiers for diabetes complications. We aimed to determine whether ranirestat, an ARI, could slow or reverse the course of diabetic sensorimotor polyneuropathy (DSP). RESEARCH DESIGN AND METHODS: A total of 549 patients with DSP we...
Autores principales: | Bril, Vera, Hirose, Toshiyuki, Tomioka, Sasagu, Buchanan, Robert |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699746/ https://www.ncbi.nlm.nih.gov/pubmed/19366965 http://dx.doi.org/10.2337/dc08-2110 |
Ejemplares similares
-
Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy
por: Bril, V, et al.
Publicado: (2009) -
Conduction Slowing in Diabetic Sensorimotor Polyneuropathy
por: Dunnigan, Samantha K., et al.
Publicado: (2013) -
Ranirestat Improves Electrophysiologic but not Clinical Measures of Diabetic Polyneuropathy: A Meta-Analysis
por: Dutta, Deep, et al.
Publicado: (2022) -
Heart Rate Variability and Sensorimotor Polyneuropathy in Type 1 Diabetes
por: Orlov, Steven, et al.
Publicado: (2012) -
Comparison of diabetes patients with “demyelinating” diabetic sensorimotor polyneuropathy to those diagnosed with CIDP
por: Dunnigan, Samantha K, et al.
Publicado: (2013)